Recent advances in rectal cancer treatment – are we on the right track?
Keywords:
Locally advanced rectal cancer, organ preservation, watch and wait, total neoadjuvant treatment
Abstract
Background: Staging and treatment of rectal cancer have evolved over several decades with considerably fewer locoregional recurrences but no marked improved survival since systemic recurrence risks remain virtually unchanged. This development will briefly be summarised followed by a thorough discussion of two recent developments.
Methods: A systematic approach towards the literature is aimed at focusing on organ preservation and the delivery of all non-surgical treatments prior to surgery or total neoadjuvant treatment (TNT).
Results: Organ preservation, that is to defer surgery if the tumour happens to disappear completely after any pre-treatment given to locally advanced tumours to decrease recurrence risks has increased in popularity and is, if not universally, widely accepted. To give neo-adjuvant treatment to intentionally obtain a clinically complete remission to avoid surgery is practised in some environments but is mostly still experimental. TNT, that is to provide both radiotherapy and chemotherapy aimed at killing microscopic disease in the pelvis or elsewhere has been subject to several trials. Collectively, they show that the chance of achieving a complete response, pathologically or clinically, has approximately doubled, increasing the chance for organ preservation, and the risk of distant metastasis has decreased at least in some trials. The best schedule remains to be established.
Conclusions: To obtain substantial progress and also improve survival, the systemic treatments need to be improved even if preoperative delivery is more effective and better tolerated than postoperative. The locoregional treatment may be further optimised through better risk prediction.
Downloads
Download data is not yet available.
References
1. Aschele C, Glynne-Jones R. Selecting a TNT schedule in locally advanced rectal cancer: can we predict who actually benefits? Cancers (Basel) 2023;15:2567. doi: 10.3390/cancers15092567
2. Kennecke HF, Bahnson HT, Lin B, O’Rourke C, Kaplan J, Pham H, et al. Patterns of practice and improvements in survival among patients with stage 2/3 rectal cancer treated with trimodality therapy. JAMA Oncol. 2022;8:1466–70. doi: 10.1001/jamaoncol.2022.2831
3. Storli PE, Dille-Amdam RG, Skjaerseth GH, Gran MV, Myklebust TA, Gronbech JE, et al. Cumulative incidence of first recurrence after curative treatment of stage I-III colorectal cancer. Competing risk analyses of temporal and anatomic patterns. Acta Oncol. 2023;62:1822–30. doi: 10.1080/0284186X.2023.2269644
4. Waldenstedt S, Haglind E, Angenete E. Symptoms and diagnosis of local recurrence after rectal cancer treatment. Acta Oncol. 2022;61:1043–9. doi: 10.1080/0284186X.2022.2106794
5. Glimelius B. Multidisciplinary treatment of patients with rectal cancer: development during the past decades and plans for the future. Ups J Med Sci. 2012;117:225–36. doi: 10.3109/03009734.2012.658974
6. Glimelius B. On a prolonged interval between rectal cancer (chemo)radiotherapy and surgery. Ups J Med Sci. 2017;122:1–10. doi: 10.1080/03009734.2016.1274806
7. Heald RJ, Ryall RDH. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986;28:1479–82. doi: 10.1016/S0140-6736(86)91510-2
8. Påhlman L, Glimelius B. Pre- or postoperative radiotherapy in rectal carcinoma: a report from a randomized multicenter trial. Ann Surg. 1990;211:187–95. doi: 10.1097/00000658-199002000-00011
9. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336:980–7. doi: 10.1056/NEJM199704033361402
10. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638–46. doi: 10.1056/NEJMoa010580
11. Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U, Jr., Silva e Sousa AH, Jr., et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240:711–7. doi: 10.1097/01.sla.0000141194.27992.32
12. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40. doi: 10.1056/NEJMoa040694
13. Guillou PJ, Quirke P, Thorpe H, Walker J, Jayne DG, Smith AM, et al. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet. 2005;365:1718–26. doi: 10.1016/S0140-6736(05)66545-2
14. MERCURY Study Group. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology. 2007;243:132–9. doi: 10.1148/radiol.2431051825
15. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114–23. doi: 10.1056/NEJMoa060829
16. Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24:4620–5. doi: 10.1200/JCO.2006.06.7629
17. Holm T, Ljung A, Haggmark T, Jurell G, Lagergren J. Extended abdominoperineal resection with gluteus maximus flap reconstruction of the pelvic floor for rectal cancer. Br J Surg. 2007;94:232–8. doi: 10.1002/bjs.5489
18. Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol. 2008;26:303–12. doi: 10.1200/JCO.2007.12.7027
19. Braendengen M, Tveit KM, Berglund Å, Birkemeyer E, Frykholm G, Påhlman L, et al. A randomized phase III study (LARCS) comparing preoperative radiotherapy alone versus chemoradiotherapy in non-resectable rectal cancer. J Clin Oncol. 2008;26:3687–94. doi: 10.1200/JCO.2007.15.3858
20. Radu C, Berglund Å, Påhlman L, Glimelius B. Short course preoperative radiotherapy with delayed surgery in rectal cancer – a retrospective study. Radiother Oncol. 2008;87:343–9. doi: 10.1016/j.radonc.2007.11.025
21. Hatfield P, Hingorani M, Radhakrishna G, Cooper R, Melcher A, Crellin A, et al. Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity. Radiother Oncol. 2009;92:210–4. doi: 10.1016/j.radonc.2009.04.007
22. Blomqvist L, Glimelius B. The ‘good’, the ‘bad’, and the ‘ugly’ rectal cancers. Acta Oncol. 2008;47:5–8. doi: 10.1080/02841860701802585
23. Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;373:811–20. doi: 10.1016/S0140-6736(09)60484-0
24. Glimelius B, Beets-Tan R, Blomqvist L, Brown G, Nagtegaal I, Pahlman L, et al. Mesorectal fascia instead of circumferential resection margin in preoperative staging of rectal cancer. J Clin Oncol. 2011;29:2142–3. doi: 10.1200/JCO.2010.34.4473
25. Maas M, Nelemans PJ, Valentini V, Das P, Rodel C, Kuo LJ, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835–44. doi: 10.1016/S1470-2045(10)70172-8
26. Maas M, Beets-Tan RG, Lambregts DM, Lammering G, Nelemans PJ, Engelen SM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29:4633–40. doi: 10.1200/JCO.2011.37.7176
27. Rodel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012;13:679–87. doi: 10.1016/S1470-2045(12)70187-0
28. Gerard JP, Azria D, Gourgou-Bourgade S, Martel-Lafay I, Hennequin C, Etienne PL, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol. 2012;30:4558–65. doi: 10.1200/JCO.2012.42.8771
29. O’Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol. 2014;32:1927–34. doi: 10.1200/JCO.2013.53.7753
30. Schmoll HJ, Cunningham D, Sobrero A, Karapetis CS, Rougier P, Koski SL, et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol. 2012;30:3588–95. doi: 10.1200/JCO.2012.42.5355
31. Jayne D, Pigazzi A, Marshall H, Croft J, Corrigan N, Copeland J, et al. Effect of robotic-assisted vs conventional laparoscopic surgery on risk of conversion to open laparotomy among patients undergoing resection for rectal cancer: the ROLARR randomized clinical trial. JAMA. 2017;318:1569–80. doi: 10.1001/jama.2017.7219
32. Erlandsson J, Holm T, Pettersson D, Berglund A, Cedermark B, Radu C, et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol. 2017;18:336–46. doi: 10.1016/S1470-2045(17)30086-4
33. Bahadoer R, Dijkstra E, van Etten B, Marijnen C, Putter H, Meershoek-Klein Kranenbarg E, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:29–42. doi: 10.1016/S1470-2045(20)30555-6
34. Conroy T, Bosset JF, Etienne PL, Rio E, Francois E, Mesgouez-Nebout N, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:702–15. doi: 10.1016/S1470-2045(21)00079-6
35. Folkesson J, Birgisson H, Påhlman L, Cedermark B, Glimelius B, Gunnarsson U. Swedish rectal cancer trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23:5644–50. doi: 10.1200/JCO.2005.08.144
36. van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575–82. doi: 10.1016/S1470-2045(11)70097-3
37. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M, et al. Long-term results of a randomised trial comparing preoperative short-course radiotherapy vs preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93:1215–23. doi: 10.1002/bjs.5506
38. Ngan S, Fisher R, Goldstein D, Solomon M, Burmeister B., Ackland SP, Joseph DJ, et al. A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: an intergroup trial (TROG, AGITG, CSSANZ, RACS). J Clin Oncol. 2010;28:15s.doi: 10.1200/jco.2010.28.15_suppl.3509
39. Glimelius B, Isacsson U. Preoperative radiotherapy for rectal cancer – is 5 x 5 Gy a good or a bad schedule? Acta Oncol. 2001;40:958–67. doi: 10.1080/02841860152708242
40. Pettersson D, Cedermark B, Holm T, Radu C, Pahlman L, Glimelius B, et al. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg. 2010;97:580–7. doi: 10.1002/bjs.6914
41. Petersen SH, Harling H, Kirkeby LT, Wille-Jorgensen P, Mocellin S. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev. 2012;3:CD004078. doi: 10.1002/14651858.CD004078.pub2
42. Breugom AJ, Swets M, Bosset JF, Collette L, Sainato A, Cionini L, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16:200–7. doi: 10.1016/S1470-2045(14)71199-4
43. Bujko K, Glimelius B, Valentini V, Michalski W, Spalek M. Postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo)therapy: a meta-analysis of randomized trials comparing surgery +/- a fluoropyrimidine and surgery + a fluoropyrimidine +/- oxaliplatin. Eur J Surg Oncol. 2015;41:713–23. doi: 10.1016/j.ejso.2015.03.233
44. Glimelius B. Adjuvant chemotherapy in rectal cancer: state of the art and future perspectives. Curr Opin Oncol. 2020;32:377–83. doi: 10.1097/CCO.0000000000000641
45. Dijkstra EA, Zwart WH, Nilsson PJ, Putter H, Roodvoets AGH, Meershoek-Klein Kranenbarg E, et al. The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer-results from the RAPIDO trial. ESMO Open. 2023;8:101158. doi: 10.1016/j.esmoop.2023.101158
46. D’Souza N, de Neree Tot Babberich MPM, d’Hoore A, Tiret E, Xynos E, Beets-Tan RGH, et al. Definition of the rectum: an international, expert-based Delphi consensus. Ann Surg. 2019;270:955–9. doi: 10.1097/SLA.0000000000003251
47. Hammarstrom K, Mezheyeuski A, Korsavidou Hult N, Sjoblom T, Glimelius B. Stage distribution utilizing magnetic resonance imaging in an unselected population of primary rectal cancers. Eur J Surg Oncol. 2018;44:1858–64. doi: 10.1016/j.ejso.2018.07.063
48. Hammarstrom K, Imam I, Korsavidou Hult N, Ekstrom J, Sjoblom T, Glimelius B. Determining the use of preoperative (chemo)radiotherapy in primary rectal cancer according to national and international guidelines. Radiother Oncol. 2019;136:106–12. doi: 10.1016/j.radonc.2019.03.036
49. Brouwer NPM, Stijns RCH, Lemmens V, Nagtegaal ID, Beets-Tan RGH, Futterer JJ, et al. Clinical lymph node staging in colorectal cancer; a flip of the coin?. Eur J Surg Oncol. 2018;44:1241–6. doi: 10.1016/j.ejso.2018.04.008
50. Imam I, Hammarstrom K, Glimelius B. Determinants of pre-surgical treatment in primary rectal cancer: a population-based study. Cancers (Basel). 2023;15:1154. doi: 10.3390/cancers15041154
51. Lehtonen TM, Ilvesmaki A, Koskenvuo LE, Lepisto AH. The ability of magnetic resonance imaging to predict lymph node metastases and the risk of recurrence in rectal cancer. J Surg Oncol. 2023;127:991–8. doi: 10.1002/jso.27216
52. RCC. National Care Programme. 2020. Available from: https://kunskapsbankencancercentrumse/diagnoser/tjock-och-andtarmscancer/vardprogram/ [cited October 2022].
53. Bujko K, Wyrwicz L, Rutkowski A, Malinowska M, Pietrzak L, Krynski J, et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 x 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol. 2016;27:834–42. doi: 10.1093/annonc/mdw062
54. Wang J, Zhang L, Wang M, Zhang J, Wang Y, Wan J, et al. Long-term outcomes in a retrospective cohort of patients with rectal cancer with complete response after total neoadjuvant therapy: a propensity-score weighted analysis. Ther Adv Med Oncol. 2023;15:17588359231197955. doi: 10.1177/17588359231197955
55. van der Valk MJM, Hilling DE, Bastiaannet E, Meershoek-Klein Kranenbarg E, Beets GL, Figueiredo NL, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391:2537–45. doi: 10.1016/S0140-6736(18)31078-X
56. Nilsson PJ, Ahlberg M, Kordnejad S, Holm T, Martling A. Organ preservation following short-course radiotherapy for rectal cancer. BJS Open. 2021;5: rab093. doi: 10.1093/bjsopen/zrab093
57. Temmink SJD, Peeters K, Bahadoer RR, Kranenbarg EM, Roodvoets AGH, Melenhorst J, et al. Watch and wait after neoadjuvant treatment in rectal cancer: comparison of outcomes in patients with and without a complete response at first reassessment in the International Watch & Wait Database (IWWD). Br J Surg. 2023;110:676–84. doi: 10.1093/bjs/znad051
58. Fernandez LM, Sao Juliao GP, Figueiredo NL, Beets GL, van der Valk MJM, Bahadoer RR, et al. Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study. Lancet Oncol. 2021;22:43–50. doi: 10.1016/S1470-2045(20)30557-X
59. Tan S, Gao Q, Cui Y, Ou Y, Huang S, Feng W. Oncologic outcomes of watch-and-wait strategy or surgery for low to intermediate rectal cancer in clinical complete remission after adjuvant chemotherapy: a systematic review and meta-analysis. Int J Colorectal Dis. 2023;38:246. doi: 10.1007/s00384-023-04534-2
60. Hall WA, Smith JJ. Achieving a cure without total mesorectal excision in rectal adenocarcinoma. J Clin Oncol. 2023;41:173–80. doi: 10.1200/JCO.22.01812
61. Socha J, Bujko K. The ultimate local failure rate after the watch-and-wait strategy for rectal cancer: a systematic review of literature and meta-analysis. Acta Oncol. 2023;62:1052–65. doi: 10.1080/0284186X.2023.2245553
62. Fokas E, Appelt A, Glynne-Jones R, Beets G, Perez R, Garcia-Aguilar J, et al. International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. Nat Rev Clin Oncol. 2021;18:805–16. doi: 10.1038/s41571-021-00538-5
63. Colloca G, Venturino A, Vitucci P. Pre-treatment carcinoembryonic antigen and outcome of patients with rectal cancer receiving neo-adjuvant chemo-radiation and surgical resection: a systematic review and meta-analysis. Med Oncol. 2017;34:177. doi: 10.1007/s12032-017-1037-8
64. Hammarstrom K, Imam I, Mezheyeuski A, Ekstrom J, Sjoblom T, Glimelius B. A comprehensive evaluation of associations between routinely collected staging information and the response to (chemo)radiotherapy in rectal cancer. Cancers (Basel). 2020;13:16. doi: 10.3390/cancers13010016
65. Donnelly SM, Wyatt J, Powell SG, Jones N, Altaf K, Ahmed S. What is the optimal timing of surgery after short-course radiotherapy for rectal cancer? Surg Oncol. 2023;51:101992. doi: 10.1016/j.suronc.2023.101992
66. Guzman Y, Rios J, Paredes J, Dominguez P, Maurel J, Gonzalez-Abos C, et al. Time interval between the end of neoadjuvant therapy and elective resection of locally advanced rectal cancer in the CRONOS study. JAMA Surg. 2023;158:910–9. doi: 10.1001/jamasurg.2023.2521
67. Cambray M, Gonzalez-Viguera J, Losa F, Martinez-Villacampa M, Frago R, Mata F, et al. Determining the optimal interval between neoadjuvant radiochemotherapy and surgery in rectal cancer: a retrospective cohort study. Int J Colorectal Dis. 2023;38:154. doi: 10.1007/s00384-023-04457-y
68. Aslanov K, Atici AE, Karaman D, Bozkurtlar E, Yegen SC. Optimal waiting period to surgical treatment after neoadjuvant chemoradiotherapy for locally advanced rectum cancer: a retrospective observational study. Langenbecks Arch Surg. 2023;408:210. doi: 10.1007/s00423-023-02930-4
69. Lefevre JH, Mineur L, Kotti S, Rullier E, Rouanet P, de Chaisemartin C, et al. Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol. 2016;34:3773–80. doi: 10.1200/JCO.2016.67.6049
70. Lefevre JH, Mineur L, Cachanado M, Denost Q, Rouanet P, de Chaisemartin C, et al. Does a longer waiting period after neoadjuvant radio-chemotherapy improve the oncological prognosis of rectal cancer?: three years’ follow-up results of the Greccar-6 randomized multicenter trial. Ann Surg. 2019;270:747–54. doi: 10.1097/SLA.0000000000003530
71. Terzi C, Bingul M, Arslan NC, Ozturk E, Canda AE, Isik O, et al. Randomized controlled trial of 8 weeks’ vs 12 weeks’ interval between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer. Colorectal Dis. 2020;22:279–88. doi: 10.1111/codi.14867
72. Akgun E, Caliskan C, Bozbiyik O, Yoldas T, Doganavsargil B, Ozkok S, et al. Effect of interval between neoadjuvant chemoradiotherapy and surgery on disease recurrence and survival in rectal cancer: long-term results of a randomized clinical trial. BJS Open. 2022;6:zrac107. doi: 10.1093/bjsopen/zrac107
73. Evans J, Bhoday J, Sizer B, Tekkis P, Swift R, Perez R, et al. Results of a prospective randomised control 6 vs 12 trial: is greater tumour downstaging observed on post treatment MRI if surgery is delayed to 12-weeks versus 6-weeks after completion of neoadjuvant chemoradiotherapy? ESMO. 2016;27:Abstr 4520. doi: 10.1093/annonc/mdw370.01
74. Hupkens BJP, Maas M, Martens MH, van der Sande ME, Lambregts DMJ, Breukink SO, et al. Organ preservation in rectal cancer after chemoradiation: should we extend the observation period in patients with a clinical near-complete response?. Ann Surg Oncol. 2018;25:197–203. doi: 10.1245/s10434-017-6213-8
75. Thompson HM, Omer DM, Lin S, Kim JK, Yuval JB, Veheij FS, et al. Organ preservation and survival by clinical response grade in patients with rectal cancer treated with total neoadjuvant therapy: a secondary analysis of the OPRA randomized clinical trial. JAMA Netw Open. 2024;7:e2350903. doi: 10.1001/jamanetworkopen.2023.50903
76. Holdakowska A, Gerard JP, Bujko K. The importance of measuring baseline tumour volume (or alternatively tumour length along with its rectal circumferential extent) in the watch-and-wait strategy in rectal cancer: a review. Acta Oncol. 2022;61:1084–92. doi: 10.1080/0284186X.2022.2122866
77. Hodges N, Battersby N, Rao S, Brown G, Group TS. Relationship between baseline rectal tumor length and magnetic resonance tumor regression grade response to chemoradiotherapy: a subanalysis of the TRIGGER feasibility study. Ann Surg Oncol. 2023;30:4729–35. doi: 10.1245/s10434-022-11914-5
78. Appelt AL, Ploen J, Harling H, Jensen FS, Jensen LH, Jorgensen JC, et al. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol. 2015;16:919–27. doi: 10.1016/S1470-2045(15)00120-5
79. Gerard JP, Barbet N, Schiappa R, Magne N, Martel I, Mineur L, et al. Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2–cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2023;8:356–67. doi: 10.1016/S2468-1253(22)00392-2
80. Grabenbauer A, Aigner T, Gobel H, Leibl BJ, Lamberti C, Grabenbauer GG, et al. Preoperative radiochemotherapy in rectal cancer: is there an impact of oxaliplatin on pathologic complete response and survival rates under “real world” conditions?. Cells. 2023;12:399. doi: 10.3390/cells12030399
81. Kennecke HF, O’Callaghan CJ, Loree JM, Moloo H, Auer R, Jonker DJ, et al. Neoadjuvant chemotherapy, excision, and observation for early rectal cancer: the phase II NEO trial (CCTG CO.28) primary end point results. J Clin Oncol. 2023;41:233–42. doi: 10.1200/JCO.22.00184
82. Akiyoshi T, Shinozaki E, Taguchi S, Chino A, Hiratsuka M, Tominaga T, et al. Non-operative management after chemoradiotherapy plus consolidation or sandwich (induction with bevacizumab and consolidation) chemotherapy in patients with locally advanced rectal cancer: a multicentre, randomised phase II trial (NOMINATE trial). BMJ Open. 2022;12:e055140. doi: 10.1136/bmjopen-2021-055140
83. Cisel B, Pietrzak L, Michalski W, Wyrwicz L, Rutkowski A, Kosakowska E, et al. Long-course preoperative chemoradiation vs. 5 x 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol. 2019;30:1298–303. doi: 10.1093/annonc/mdz186
84. Dijkstra EA, Nilsson PJ, Hospers GAP, Bahadoer RR, Meershoek-Klein Kranenbarg E, Roodvoets AGH, et al. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial. Ann Surg. 2023;278:e766–e72. doi: 10.1097/SLA.0000000000005799
85. Jin J, Tang Y, Hu C, Jiang LM, Jiang J, Li N, et al. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol. 2022;40:1681–92. doi: 10.1200/JCO.21.01667
86. Fernandez-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol. 2010;28:859–65. doi: 10.1200/JCO.2009.25.8541
87. Borg C, Andre T, Mantion G, Boudghene F, Mornex F, Maingon P, et al. Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study. Ann Oncol. 2014;25:2205–10. doi: 10.1093/annonc/mdu377
88. Moore J, Price T, Carruthers S, Selva-Nayagam S, Luck A, Thomas M, et al. Prospective randomized trial of neoadjuvant chemotherapy during the ‘wait period’ following preoperative chemoradiotherapy for rectal cancer: results of the WAIT trial. Colorectal Dis. 2017;19:973–9. doi: 10.1111/codi.13724
89. Kim SY, Joo J, Kim TW, Hong YS, Kim JE, Hwang IG, et al. A randomized phase 2 trial of consolidation chemotherapy after preoperative chemoradiation therapy versus chemoradiation therapy alone for locally advanced rectal cancer: KCSG CO 14-03. Int J Radiat Oncol Biol Phys 2018;101:889–99. doi: 10.1016/j.ijrobp.2018.04.013
90. Marechal R, Vos B, Polus M, Delaunoit T, Peeters M, Demetter P, et al. Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. Ann Oncol. 2012;23:1525–30. doi: 10.1093/annonc/mdr473
91. Rouanet P, Rullier E, Lelong B, Maingon P, Tuech JJ, Pezet D, et al. Tailored strategy for locally advanced rectal carcinoma (GRECCAR 4): long-term results from a multicenter, randomized, open-label, phase II trial. Dis Colon Rectum. 2022;65:986–95. doi: 10.1097/DCR.0000000000002153
92. Schrag D, Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL, et al. Preoperative treatment of locally advanced rectal cancer. N Engl J Med. 2023;389:322–34. doi: 10.1056/NEJMoa2303269
93. Fokas E, Schlenska-Lange A, Polat B, Klautke G, Grabenbauer GG, Fietkau R, et al. Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of the CAO/ARO/AIO-12 randomized clinical trial. JAMA Oncol. 2022;8:e215445.
94. Diefenhardt M, Schlenska-Lange A, Kuhnt T, Kirste S, Piso P, Bechstein WO, et al. Total neoadjuvant therapy for rectal cancer in the CAO/ARO/AIO-12 randomized phase 2 trial: early surrogate endpoints revisited. Cancers (Basel). 2022;14:3658. doi: 10.3390/cancers14153658
95. Diefenhardt M, Fleischmann M, Martin D, Hofheinz RD, Piso P, Germer CT, et al. Clinical outcome after total neoadjuvant treatment (CAO/ARO/AIO-12) versus intensified neoadjuvant and adjuvant treatment (CAO/ARO/AIO-04) a comparison between two multicenter randomized phase II/III trials. Radiother Oncol. 2023;179:109455. doi: 10.1016/j.radonc.2022.109455
96. Deng Y, Chi P, Lan P, Wang L, Chen W, Cui L, et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase III trial. J Clin Oncol. 2016;34:3300–7. doi: 10.1200/JCO.2016.66.6198
97. Deng Y, Chi P, Lan P, Wang L, Chen W, Cui L, et al. Neoadjuvant modified FOLFOX6 with or without radiation versus dluorouracil plus radiation for locally advanced rectal cancer: final results of the Chinese FOWARC trial. J Clin Oncol. 2019;37:3223–33. doi: 10.1200/JCO.18.02309
98. Garcia-Aguilar J, Patil S, Gollub MJ, Kim JK, Yuval JB, Thompson HM, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022;40:2546–56. doi: 10.1200/JCO.22.00032
99. Pesantez D, Ten Hoorn S, Machado I, Garcia-Albeniz X, Rodriguez-Salas N, Heredia-Soto V, et al. Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402. J Natl Cancer Inst. 2023;115:1497–505. doi: 10.1093/jnci/djad120
100. Sclafani F, Brown G, Cunningham D, Wotherspoon A, Tait D, Peckitt C, et al. PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer. Ann Oncol. 2016;27:1557–65. doi: 10.1093/annonc/mdw215
101. Garcia-Aguilar J, Chow OS, Smith DD, Marcet JE, Cataldo PA, Varma MG, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015;16:957–66. doi: 10.1016/S1470-2045(15)00004-2
102. Marco MR, Zhou L, Patil S, Marcet JE, Varma MG, Oommen S, et al. Consolidation mFOLFOX6 chemotherapy after chemoradiotherapy improves survival in patients with locally advanced rectal cancer: final results of a multicenter phase II trial. Dis Colon Rectum. 2018;61:1146–55. doi: 10.1097/DCR.0000000000001207
103. Ng SP, Chu J, Chander S, Bressel M, McKendrick J, Wong R, et al. Results of phase II trial of intensified neoadjuvant treatment with interdigitating radiotherapy and chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with locally advanced rectal cancer (PROARCT trial). Radiother Oncol. 2021;155:27–32. doi: 10.1016/j.radonc.2020.10.012
104. Engels B, De Paoli A, Delmastro E, Munoz F, Vagge S, Norkus D, et al. Preoperative radiotherapy with a simultaneous integrated boost compared to chemoradiotherapy for cT3–4 rectal cancer: long-term results of a multicenter randomized study. Cancers (Basel). 2023;15:3869. doi: 10.3390/cancers15153869
105. Yamaguchi T, Akiyoshi T, Fukunaga Y, Sakamoto T, Mukai T, Hiyoshi Y, et al. Adding induction chemotherapy before chemoradiotherapy with total mesorectal excision and selective lateral lymph node dissection for patients with poor-risk, locally advanced, mid-to-low rectal cancer may improve oncologic outcomes: a propensity score-matched analysis. Ann Surg Oncol. 2023;30:4716–24. doi: 10.1245/s10434-023-13458-8
106. Nogue M, Salud A, Vicente P, Arrivi A, Roca JM, Losa F, et al. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study. Oncologist. 2011;16:614–20. doi: 10.1634/theoncologist.2010-0285
107. Benlice C, Koc MA, Gulcu B, Bilgin IA, Akyol C, Baca B, et al. Short-course radiotherapy followed by consolidation chemotherapy is safe and effective in locally advanced rectal cancer: comparative short-term results of multicenter propensity score case-matched study. Dis Colon Rectum. 2023;66:681–90. doi: 10.1097/DCR.0000000000002646
108. Moyer AM, Vogel JD, Lai SH, Kim H, Chin RI, Moskalenko M, et al. Total neoadjuvant therapy in rectal cancer: multi-center comparison of induction chemotherapy and long-course chemoradiation versus short-course radiation and consolidative chemotherapy. J Gastrointest Surg. 2023;27:980–9. doi: 10.1007/s11605-023-05601-3
109. Chin RI, Roy A, Pedersen KS, Huang Y, Hunt SR, Glasgow SC, et al. Clinical complete response in patients with rectal adenocarcinoma treated with short-course radiation therapy and nonoperative management. Int J Radiat Oncol Biol Phys. 2022;112:715–25. doi: 10.1016/j.ijrobp.2021.10.004
110. Hall WA, Li J, You YN, Gollub MJ, Grajo JR, Rosen M, et al. Prospective correlation of magnetic resonance tumor regression grade with pathologic outcomes in total neoadjuvant therapy for rectal adenocarcinoma. J Clin Oncol. 2023;41:4643–51. doi: 10.1200/JCO.22.02525
111. Gollins S, West N, Sebag-Montefiore D, Susnerwala S, Falk S, Brown N, et al. A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS. Br J Cancer. 2018;119:697–706. doi: 10.1038/s41416-018-0209-4
112. Myerson RJ, Tan B, Hunt S, Olsen J, Birnbaum E, Fleshman J, et al. Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer. Int J Radiat Oncol Biol Phys 2014;88:829–36. doi: 10.1016/j.ijrobp.2013.12.028
113. Markovina S, Youssef F, Roy A, Aggarwal S, Khwaja S, DeWees T, et al. Improved metastasis- and disease-free survival with preoperative sequential short-course radiation therapy and FOLFOX chemotherapy for rectal cancer compared with neoadjuvant long-course chemoradiotherapy: results of a matched pair analysis. Int J Radiat Oncol Biol Phys. 2017;99:417–26. doi: 10.1016/j.ijrobp.2017.05.048
114. Kim JK, Marco MR, Roxburgh CSD, Chen CT, Cercek A, Strombom P, et al. Survival after induction chemotherapy and chemoradiation versus chemoradiation and adjuvant chemotherapy for locally advanced rectal cancer. Oncologist. 2022;27:380–8. doi: 10.1093/oncolo/oyac025
115. Garant A, Kavan P, Martin AG, Azoulay L, Vendrely V, Lavoie C, et al. Optimizing treatment sequencing of chemotherapy for patients with rectal cancer: the KIR randomized phase II trial. Radiother Oncol. 2021;155:237–45. doi: 10.1016/j.radonc.2020.11.008
116. Goffredo P, Khan A, Mott SL, Jensen CC, Madoff RD, Gaertner WB, et al. Total neoadjuvant therapy versus standard neoadjuvant chemoradiation in patients with locally advanced rectal cancer: a comparison of short- and long-term oncologic outcomes. Ann Surg. 2022;276:e819–e24. doi: 10.1097/SLA.0000000000005141
117. Cercek A, Roxburgh CSD, Strombom P, Smith JJ, Temple LKF, Nash GM, et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol. 2018;4:e180071. doi: 10.1001/jamaoncol.2018.0071
118. Patel UB, Brown G, Machado I, Santos-Cores J, Pericay C, Ballesteros E, et al. MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial. Ann Oncol. 2017;28:344–53. doi: 10.1093/annonc/mdw616
119. Uehara K, Hiramatsu K, Maeda A, Sakamoto E, Inoue M, Kobayashi S, et al. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial. Jpn J Clin Oncol. 2013;43:964–71. doi: 10.1093/jjco/hyt115
120. Ishii Y, Hasegawa H, Endo T, Okabayashi K, Ochiai H, Moritani K, et al. Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer. Eur J Surg Oncol. 2010;36:1061–5. doi: 10.1016/j.ejso.2010.05.017
121. Mukai T, Uehara K, Aiba T, Ogura A, Tsuzuki T, Tanaka A, et al. Importance of the neoadjuvant rectal (NAR) score to the outcome of neoadjuvant chemotherapy alone for locally advanced rectal cancer. Surg Today. 2020;50:912–9. doi: 10.1007/s00595-020-01964-1
122. Matsuda C, Ishiguro M, Teramukai S, Kajiwara Y, Fujii S, Kinugasa Y, et al. A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial. Eur J Cancer. 2018;96:54–63. doi: 10.1016/j.ejca.2018.03.009
123. Dahl O. Watch your steps, especially when changing treatment for locally advanced rectal cancer. Acta Oncol. 2022;61:1033–5. doi: 10.1080/0284186X.2022.2053574
124. van der Valk MJM, Marijnen CAM, van Etten B, Dijkstra EA, Hilling DE, Kranenbarg EM, et al. Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer – results of the international randomized RAPIDO-trial. Radiother Oncol. 2020;147:75–83. doi: 10.1016/j.radonc.2020.03.011
125. Bauer PS, Gamboa AC, Otegbeye EE, Chapman WC, Rivard S, Regenbogen S, et al. Short-course radiation with consolidation chemotherapy does not increase operative morbidity compared to long-course chemoradiation: a retrospective study of the US rectal cancer consortium. J Surg Oncol. 2023;129:254–63. doi: 10.1002/jso.27468
126. Guida AM, Sensi B, Formica V, D’Angelillo RM, Roselli M, Del Vecchio Blanco G, et al. Total neoadjuvant therapy for the treatment of locally advanced rectal cancer: a systematic minireview. Biol Direct. 2022;17:16. doi: 10.1186/s13062-022-00329-7
127. Sao Juliao GP, Fernandez LM, Vailati BB, Habr-Gama A, Azevedo J, Santiago I, et al. Local regrowth and the risk of distant metastases among patients undergoing watch-and-wait for rectal cancer: what is the best control group? Muticenter retrospective study. Dis Colon Rectum. 2023;73–81. doi: 10.1097/DCR.0000000000002930
128. Hoendervangers S, Couwenberg AM, Intven MPW, van Grevenstein WMU, Verkooijen HM. Comparison of pathological complete response rates after neoadjuvant short-course radiotherapy or chemoradiation followed by delayed surgery in locally advanced rectal cancer. Eur J Surg Oncol. 2018;44:1013–7. doi: 10.1016/j.ejso.2018.03.014
129. Cervantes A, Adam R, Rosello S, Arnold D, Normanno N, Taieb J, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:10–32. doi: 10.1016/j.annonc.2022.10.003
130. Osterlund E, Glimelius B. Temporal development in survival, and gender and regional differences in the Swedish population of patients with synchronous and metachronous metastatic colorectal cancer. Acta Oncol. 2022;61:1278–88. doi: 10.1080/0284186X.2022.2126327
131. Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022;386:2363–76. doi: 10.1056/NEJMoa2201445
132. Wang QX, Xiao BY, Cheng Y, Wu AW, Zhang T, Wang H, et al. Anti-PD-1-based immunotherapy as curative-intent treatment in dMMR/MSI-H rectal cancer: a multicentre cohort study. Eur J Cancer. 2022;174:176–84. doi: 10.1016/j.ejca.2022.07.016
133. Germani MM, Carullo M, Boccaccino A, Conca V, Masi G. The evolving landscape of immunotherapy in locally advanced rectal cancer patients. Cancers (Basel). 2022;14:4453. doi: 10.3390/cancers14184453
134. Osterlund E, Ristimaki A, Makinen MJ, Kytola S, Kononen J, Pfeiffer P, et al. Atypical (non-V600E) BRAF mutations in metastatic colorectal cancer in population and real-world cohorts. Int J Cancer. 2024;154:488–503. doi: 10.1002/ijc.34733
135. Yaeger R, Weiss J, Pelster MS, Spira AI, Barve M, Ou SI, et al. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023;388:44–54. doi: 10.1056/NEJMoa2212419
2. Kennecke HF, Bahnson HT, Lin B, O’Rourke C, Kaplan J, Pham H, et al. Patterns of practice and improvements in survival among patients with stage 2/3 rectal cancer treated with trimodality therapy. JAMA Oncol. 2022;8:1466–70. doi: 10.1001/jamaoncol.2022.2831
3. Storli PE, Dille-Amdam RG, Skjaerseth GH, Gran MV, Myklebust TA, Gronbech JE, et al. Cumulative incidence of first recurrence after curative treatment of stage I-III colorectal cancer. Competing risk analyses of temporal and anatomic patterns. Acta Oncol. 2023;62:1822–30. doi: 10.1080/0284186X.2023.2269644
4. Waldenstedt S, Haglind E, Angenete E. Symptoms and diagnosis of local recurrence after rectal cancer treatment. Acta Oncol. 2022;61:1043–9. doi: 10.1080/0284186X.2022.2106794
5. Glimelius B. Multidisciplinary treatment of patients with rectal cancer: development during the past decades and plans for the future. Ups J Med Sci. 2012;117:225–36. doi: 10.3109/03009734.2012.658974
6. Glimelius B. On a prolonged interval between rectal cancer (chemo)radiotherapy and surgery. Ups J Med Sci. 2017;122:1–10. doi: 10.1080/03009734.2016.1274806
7. Heald RJ, Ryall RDH. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986;28:1479–82. doi: 10.1016/S0140-6736(86)91510-2
8. Påhlman L, Glimelius B. Pre- or postoperative radiotherapy in rectal carcinoma: a report from a randomized multicenter trial. Ann Surg. 1990;211:187–95. doi: 10.1097/00000658-199002000-00011
9. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336:980–7. doi: 10.1056/NEJM199704033361402
10. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638–46. doi: 10.1056/NEJMoa010580
11. Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U, Jr., Silva e Sousa AH, Jr., et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240:711–7. doi: 10.1097/01.sla.0000141194.27992.32
12. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40. doi: 10.1056/NEJMoa040694
13. Guillou PJ, Quirke P, Thorpe H, Walker J, Jayne DG, Smith AM, et al. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet. 2005;365:1718–26. doi: 10.1016/S0140-6736(05)66545-2
14. MERCURY Study Group. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology. 2007;243:132–9. doi: 10.1148/radiol.2431051825
15. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114–23. doi: 10.1056/NEJMoa060829
16. Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24:4620–5. doi: 10.1200/JCO.2006.06.7629
17. Holm T, Ljung A, Haggmark T, Jurell G, Lagergren J. Extended abdominoperineal resection with gluteus maximus flap reconstruction of the pelvic floor for rectal cancer. Br J Surg. 2007;94:232–8. doi: 10.1002/bjs.5489
18. Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol. 2008;26:303–12. doi: 10.1200/JCO.2007.12.7027
19. Braendengen M, Tveit KM, Berglund Å, Birkemeyer E, Frykholm G, Påhlman L, et al. A randomized phase III study (LARCS) comparing preoperative radiotherapy alone versus chemoradiotherapy in non-resectable rectal cancer. J Clin Oncol. 2008;26:3687–94. doi: 10.1200/JCO.2007.15.3858
20. Radu C, Berglund Å, Påhlman L, Glimelius B. Short course preoperative radiotherapy with delayed surgery in rectal cancer – a retrospective study. Radiother Oncol. 2008;87:343–9. doi: 10.1016/j.radonc.2007.11.025
21. Hatfield P, Hingorani M, Radhakrishna G, Cooper R, Melcher A, Crellin A, et al. Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity. Radiother Oncol. 2009;92:210–4. doi: 10.1016/j.radonc.2009.04.007
22. Blomqvist L, Glimelius B. The ‘good’, the ‘bad’, and the ‘ugly’ rectal cancers. Acta Oncol. 2008;47:5–8. doi: 10.1080/02841860701802585
23. Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;373:811–20. doi: 10.1016/S0140-6736(09)60484-0
24. Glimelius B, Beets-Tan R, Blomqvist L, Brown G, Nagtegaal I, Pahlman L, et al. Mesorectal fascia instead of circumferential resection margin in preoperative staging of rectal cancer. J Clin Oncol. 2011;29:2142–3. doi: 10.1200/JCO.2010.34.4473
25. Maas M, Nelemans PJ, Valentini V, Das P, Rodel C, Kuo LJ, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835–44. doi: 10.1016/S1470-2045(10)70172-8
26. Maas M, Beets-Tan RG, Lambregts DM, Lammering G, Nelemans PJ, Engelen SM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29:4633–40. doi: 10.1200/JCO.2011.37.7176
27. Rodel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012;13:679–87. doi: 10.1016/S1470-2045(12)70187-0
28. Gerard JP, Azria D, Gourgou-Bourgade S, Martel-Lafay I, Hennequin C, Etienne PL, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol. 2012;30:4558–65. doi: 10.1200/JCO.2012.42.8771
29. O’Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol. 2014;32:1927–34. doi: 10.1200/JCO.2013.53.7753
30. Schmoll HJ, Cunningham D, Sobrero A, Karapetis CS, Rougier P, Koski SL, et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol. 2012;30:3588–95. doi: 10.1200/JCO.2012.42.5355
31. Jayne D, Pigazzi A, Marshall H, Croft J, Corrigan N, Copeland J, et al. Effect of robotic-assisted vs conventional laparoscopic surgery on risk of conversion to open laparotomy among patients undergoing resection for rectal cancer: the ROLARR randomized clinical trial. JAMA. 2017;318:1569–80. doi: 10.1001/jama.2017.7219
32. Erlandsson J, Holm T, Pettersson D, Berglund A, Cedermark B, Radu C, et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol. 2017;18:336–46. doi: 10.1016/S1470-2045(17)30086-4
33. Bahadoer R, Dijkstra E, van Etten B, Marijnen C, Putter H, Meershoek-Klein Kranenbarg E, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:29–42. doi: 10.1016/S1470-2045(20)30555-6
34. Conroy T, Bosset JF, Etienne PL, Rio E, Francois E, Mesgouez-Nebout N, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:702–15. doi: 10.1016/S1470-2045(21)00079-6
35. Folkesson J, Birgisson H, Påhlman L, Cedermark B, Glimelius B, Gunnarsson U. Swedish rectal cancer trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23:5644–50. doi: 10.1200/JCO.2005.08.144
36. van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575–82. doi: 10.1016/S1470-2045(11)70097-3
37. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M, et al. Long-term results of a randomised trial comparing preoperative short-course radiotherapy vs preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93:1215–23. doi: 10.1002/bjs.5506
38. Ngan S, Fisher R, Goldstein D, Solomon M, Burmeister B., Ackland SP, Joseph DJ, et al. A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: an intergroup trial (TROG, AGITG, CSSANZ, RACS). J Clin Oncol. 2010;28:15s.doi: 10.1200/jco.2010.28.15_suppl.3509
39. Glimelius B, Isacsson U. Preoperative radiotherapy for rectal cancer – is 5 x 5 Gy a good or a bad schedule? Acta Oncol. 2001;40:958–67. doi: 10.1080/02841860152708242
40. Pettersson D, Cedermark B, Holm T, Radu C, Pahlman L, Glimelius B, et al. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg. 2010;97:580–7. doi: 10.1002/bjs.6914
41. Petersen SH, Harling H, Kirkeby LT, Wille-Jorgensen P, Mocellin S. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev. 2012;3:CD004078. doi: 10.1002/14651858.CD004078.pub2
42. Breugom AJ, Swets M, Bosset JF, Collette L, Sainato A, Cionini L, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16:200–7. doi: 10.1016/S1470-2045(14)71199-4
43. Bujko K, Glimelius B, Valentini V, Michalski W, Spalek M. Postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo)therapy: a meta-analysis of randomized trials comparing surgery +/- a fluoropyrimidine and surgery + a fluoropyrimidine +/- oxaliplatin. Eur J Surg Oncol. 2015;41:713–23. doi: 10.1016/j.ejso.2015.03.233
44. Glimelius B. Adjuvant chemotherapy in rectal cancer: state of the art and future perspectives. Curr Opin Oncol. 2020;32:377–83. doi: 10.1097/CCO.0000000000000641
45. Dijkstra EA, Zwart WH, Nilsson PJ, Putter H, Roodvoets AGH, Meershoek-Klein Kranenbarg E, et al. The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer-results from the RAPIDO trial. ESMO Open. 2023;8:101158. doi: 10.1016/j.esmoop.2023.101158
46. D’Souza N, de Neree Tot Babberich MPM, d’Hoore A, Tiret E, Xynos E, Beets-Tan RGH, et al. Definition of the rectum: an international, expert-based Delphi consensus. Ann Surg. 2019;270:955–9. doi: 10.1097/SLA.0000000000003251
47. Hammarstrom K, Mezheyeuski A, Korsavidou Hult N, Sjoblom T, Glimelius B. Stage distribution utilizing magnetic resonance imaging in an unselected population of primary rectal cancers. Eur J Surg Oncol. 2018;44:1858–64. doi: 10.1016/j.ejso.2018.07.063
48. Hammarstrom K, Imam I, Korsavidou Hult N, Ekstrom J, Sjoblom T, Glimelius B. Determining the use of preoperative (chemo)radiotherapy in primary rectal cancer according to national and international guidelines. Radiother Oncol. 2019;136:106–12. doi: 10.1016/j.radonc.2019.03.036
49. Brouwer NPM, Stijns RCH, Lemmens V, Nagtegaal ID, Beets-Tan RGH, Futterer JJ, et al. Clinical lymph node staging in colorectal cancer; a flip of the coin?. Eur J Surg Oncol. 2018;44:1241–6. doi: 10.1016/j.ejso.2018.04.008
50. Imam I, Hammarstrom K, Glimelius B. Determinants of pre-surgical treatment in primary rectal cancer: a population-based study. Cancers (Basel). 2023;15:1154. doi: 10.3390/cancers15041154
51. Lehtonen TM, Ilvesmaki A, Koskenvuo LE, Lepisto AH. The ability of magnetic resonance imaging to predict lymph node metastases and the risk of recurrence in rectal cancer. J Surg Oncol. 2023;127:991–8. doi: 10.1002/jso.27216
52. RCC. National Care Programme. 2020. Available from: https://kunskapsbankencancercentrumse/diagnoser/tjock-och-andtarmscancer/vardprogram/ [cited October 2022].
53. Bujko K, Wyrwicz L, Rutkowski A, Malinowska M, Pietrzak L, Krynski J, et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 x 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol. 2016;27:834–42. doi: 10.1093/annonc/mdw062
54. Wang J, Zhang L, Wang M, Zhang J, Wang Y, Wan J, et al. Long-term outcomes in a retrospective cohort of patients with rectal cancer with complete response after total neoadjuvant therapy: a propensity-score weighted analysis. Ther Adv Med Oncol. 2023;15:17588359231197955. doi: 10.1177/17588359231197955
55. van der Valk MJM, Hilling DE, Bastiaannet E, Meershoek-Klein Kranenbarg E, Beets GL, Figueiredo NL, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391:2537–45. doi: 10.1016/S0140-6736(18)31078-X
56. Nilsson PJ, Ahlberg M, Kordnejad S, Holm T, Martling A. Organ preservation following short-course radiotherapy for rectal cancer. BJS Open. 2021;5: rab093. doi: 10.1093/bjsopen/zrab093
57. Temmink SJD, Peeters K, Bahadoer RR, Kranenbarg EM, Roodvoets AGH, Melenhorst J, et al. Watch and wait after neoadjuvant treatment in rectal cancer: comparison of outcomes in patients with and without a complete response at first reassessment in the International Watch & Wait Database (IWWD). Br J Surg. 2023;110:676–84. doi: 10.1093/bjs/znad051
58. Fernandez LM, Sao Juliao GP, Figueiredo NL, Beets GL, van der Valk MJM, Bahadoer RR, et al. Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study. Lancet Oncol. 2021;22:43–50. doi: 10.1016/S1470-2045(20)30557-X
59. Tan S, Gao Q, Cui Y, Ou Y, Huang S, Feng W. Oncologic outcomes of watch-and-wait strategy or surgery for low to intermediate rectal cancer in clinical complete remission after adjuvant chemotherapy: a systematic review and meta-analysis. Int J Colorectal Dis. 2023;38:246. doi: 10.1007/s00384-023-04534-2
60. Hall WA, Smith JJ. Achieving a cure without total mesorectal excision in rectal adenocarcinoma. J Clin Oncol. 2023;41:173–80. doi: 10.1200/JCO.22.01812
61. Socha J, Bujko K. The ultimate local failure rate after the watch-and-wait strategy for rectal cancer: a systematic review of literature and meta-analysis. Acta Oncol. 2023;62:1052–65. doi: 10.1080/0284186X.2023.2245553
62. Fokas E, Appelt A, Glynne-Jones R, Beets G, Perez R, Garcia-Aguilar J, et al. International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. Nat Rev Clin Oncol. 2021;18:805–16. doi: 10.1038/s41571-021-00538-5
63. Colloca G, Venturino A, Vitucci P. Pre-treatment carcinoembryonic antigen and outcome of patients with rectal cancer receiving neo-adjuvant chemo-radiation and surgical resection: a systematic review and meta-analysis. Med Oncol. 2017;34:177. doi: 10.1007/s12032-017-1037-8
64. Hammarstrom K, Imam I, Mezheyeuski A, Ekstrom J, Sjoblom T, Glimelius B. A comprehensive evaluation of associations between routinely collected staging information and the response to (chemo)radiotherapy in rectal cancer. Cancers (Basel). 2020;13:16. doi: 10.3390/cancers13010016
65. Donnelly SM, Wyatt J, Powell SG, Jones N, Altaf K, Ahmed S. What is the optimal timing of surgery after short-course radiotherapy for rectal cancer? Surg Oncol. 2023;51:101992. doi: 10.1016/j.suronc.2023.101992
66. Guzman Y, Rios J, Paredes J, Dominguez P, Maurel J, Gonzalez-Abos C, et al. Time interval between the end of neoadjuvant therapy and elective resection of locally advanced rectal cancer in the CRONOS study. JAMA Surg. 2023;158:910–9. doi: 10.1001/jamasurg.2023.2521
67. Cambray M, Gonzalez-Viguera J, Losa F, Martinez-Villacampa M, Frago R, Mata F, et al. Determining the optimal interval between neoadjuvant radiochemotherapy and surgery in rectal cancer: a retrospective cohort study. Int J Colorectal Dis. 2023;38:154. doi: 10.1007/s00384-023-04457-y
68. Aslanov K, Atici AE, Karaman D, Bozkurtlar E, Yegen SC. Optimal waiting period to surgical treatment after neoadjuvant chemoradiotherapy for locally advanced rectum cancer: a retrospective observational study. Langenbecks Arch Surg. 2023;408:210. doi: 10.1007/s00423-023-02930-4
69. Lefevre JH, Mineur L, Kotti S, Rullier E, Rouanet P, de Chaisemartin C, et al. Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol. 2016;34:3773–80. doi: 10.1200/JCO.2016.67.6049
70. Lefevre JH, Mineur L, Cachanado M, Denost Q, Rouanet P, de Chaisemartin C, et al. Does a longer waiting period after neoadjuvant radio-chemotherapy improve the oncological prognosis of rectal cancer?: three years’ follow-up results of the Greccar-6 randomized multicenter trial. Ann Surg. 2019;270:747–54. doi: 10.1097/SLA.0000000000003530
71. Terzi C, Bingul M, Arslan NC, Ozturk E, Canda AE, Isik O, et al. Randomized controlled trial of 8 weeks’ vs 12 weeks’ interval between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer. Colorectal Dis. 2020;22:279–88. doi: 10.1111/codi.14867
72. Akgun E, Caliskan C, Bozbiyik O, Yoldas T, Doganavsargil B, Ozkok S, et al. Effect of interval between neoadjuvant chemoradiotherapy and surgery on disease recurrence and survival in rectal cancer: long-term results of a randomized clinical trial. BJS Open. 2022;6:zrac107. doi: 10.1093/bjsopen/zrac107
73. Evans J, Bhoday J, Sizer B, Tekkis P, Swift R, Perez R, et al. Results of a prospective randomised control 6 vs 12 trial: is greater tumour downstaging observed on post treatment MRI if surgery is delayed to 12-weeks versus 6-weeks after completion of neoadjuvant chemoradiotherapy? ESMO. 2016;27:Abstr 4520. doi: 10.1093/annonc/mdw370.01
74. Hupkens BJP, Maas M, Martens MH, van der Sande ME, Lambregts DMJ, Breukink SO, et al. Organ preservation in rectal cancer after chemoradiation: should we extend the observation period in patients with a clinical near-complete response?. Ann Surg Oncol. 2018;25:197–203. doi: 10.1245/s10434-017-6213-8
75. Thompson HM, Omer DM, Lin S, Kim JK, Yuval JB, Veheij FS, et al. Organ preservation and survival by clinical response grade in patients with rectal cancer treated with total neoadjuvant therapy: a secondary analysis of the OPRA randomized clinical trial. JAMA Netw Open. 2024;7:e2350903. doi: 10.1001/jamanetworkopen.2023.50903
76. Holdakowska A, Gerard JP, Bujko K. The importance of measuring baseline tumour volume (or alternatively tumour length along with its rectal circumferential extent) in the watch-and-wait strategy in rectal cancer: a review. Acta Oncol. 2022;61:1084–92. doi: 10.1080/0284186X.2022.2122866
77. Hodges N, Battersby N, Rao S, Brown G, Group TS. Relationship between baseline rectal tumor length and magnetic resonance tumor regression grade response to chemoradiotherapy: a subanalysis of the TRIGGER feasibility study. Ann Surg Oncol. 2023;30:4729–35. doi: 10.1245/s10434-022-11914-5
78. Appelt AL, Ploen J, Harling H, Jensen FS, Jensen LH, Jorgensen JC, et al. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol. 2015;16:919–27. doi: 10.1016/S1470-2045(15)00120-5
79. Gerard JP, Barbet N, Schiappa R, Magne N, Martel I, Mineur L, et al. Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2–cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2023;8:356–67. doi: 10.1016/S2468-1253(22)00392-2
80. Grabenbauer A, Aigner T, Gobel H, Leibl BJ, Lamberti C, Grabenbauer GG, et al. Preoperative radiochemotherapy in rectal cancer: is there an impact of oxaliplatin on pathologic complete response and survival rates under “real world” conditions?. Cells. 2023;12:399. doi: 10.3390/cells12030399
81. Kennecke HF, O’Callaghan CJ, Loree JM, Moloo H, Auer R, Jonker DJ, et al. Neoadjuvant chemotherapy, excision, and observation for early rectal cancer: the phase II NEO trial (CCTG CO.28) primary end point results. J Clin Oncol. 2023;41:233–42. doi: 10.1200/JCO.22.00184
82. Akiyoshi T, Shinozaki E, Taguchi S, Chino A, Hiratsuka M, Tominaga T, et al. Non-operative management after chemoradiotherapy plus consolidation or sandwich (induction with bevacizumab and consolidation) chemotherapy in patients with locally advanced rectal cancer: a multicentre, randomised phase II trial (NOMINATE trial). BMJ Open. 2022;12:e055140. doi: 10.1136/bmjopen-2021-055140
83. Cisel B, Pietrzak L, Michalski W, Wyrwicz L, Rutkowski A, Kosakowska E, et al. Long-course preoperative chemoradiation vs. 5 x 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol. 2019;30:1298–303. doi: 10.1093/annonc/mdz186
84. Dijkstra EA, Nilsson PJ, Hospers GAP, Bahadoer RR, Meershoek-Klein Kranenbarg E, Roodvoets AGH, et al. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial. Ann Surg. 2023;278:e766–e72. doi: 10.1097/SLA.0000000000005799
85. Jin J, Tang Y, Hu C, Jiang LM, Jiang J, Li N, et al. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol. 2022;40:1681–92. doi: 10.1200/JCO.21.01667
86. Fernandez-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol. 2010;28:859–65. doi: 10.1200/JCO.2009.25.8541
87. Borg C, Andre T, Mantion G, Boudghene F, Mornex F, Maingon P, et al. Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study. Ann Oncol. 2014;25:2205–10. doi: 10.1093/annonc/mdu377
88. Moore J, Price T, Carruthers S, Selva-Nayagam S, Luck A, Thomas M, et al. Prospective randomized trial of neoadjuvant chemotherapy during the ‘wait period’ following preoperative chemoradiotherapy for rectal cancer: results of the WAIT trial. Colorectal Dis. 2017;19:973–9. doi: 10.1111/codi.13724
89. Kim SY, Joo J, Kim TW, Hong YS, Kim JE, Hwang IG, et al. A randomized phase 2 trial of consolidation chemotherapy after preoperative chemoradiation therapy versus chemoradiation therapy alone for locally advanced rectal cancer: KCSG CO 14-03. Int J Radiat Oncol Biol Phys 2018;101:889–99. doi: 10.1016/j.ijrobp.2018.04.013
90. Marechal R, Vos B, Polus M, Delaunoit T, Peeters M, Demetter P, et al. Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. Ann Oncol. 2012;23:1525–30. doi: 10.1093/annonc/mdr473
91. Rouanet P, Rullier E, Lelong B, Maingon P, Tuech JJ, Pezet D, et al. Tailored strategy for locally advanced rectal carcinoma (GRECCAR 4): long-term results from a multicenter, randomized, open-label, phase II trial. Dis Colon Rectum. 2022;65:986–95. doi: 10.1097/DCR.0000000000002153
92. Schrag D, Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL, et al. Preoperative treatment of locally advanced rectal cancer. N Engl J Med. 2023;389:322–34. doi: 10.1056/NEJMoa2303269
93. Fokas E, Schlenska-Lange A, Polat B, Klautke G, Grabenbauer GG, Fietkau R, et al. Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of the CAO/ARO/AIO-12 randomized clinical trial. JAMA Oncol. 2022;8:e215445.
94. Diefenhardt M, Schlenska-Lange A, Kuhnt T, Kirste S, Piso P, Bechstein WO, et al. Total neoadjuvant therapy for rectal cancer in the CAO/ARO/AIO-12 randomized phase 2 trial: early surrogate endpoints revisited. Cancers (Basel). 2022;14:3658. doi: 10.3390/cancers14153658
95. Diefenhardt M, Fleischmann M, Martin D, Hofheinz RD, Piso P, Germer CT, et al. Clinical outcome after total neoadjuvant treatment (CAO/ARO/AIO-12) versus intensified neoadjuvant and adjuvant treatment (CAO/ARO/AIO-04) a comparison between two multicenter randomized phase II/III trials. Radiother Oncol. 2023;179:109455. doi: 10.1016/j.radonc.2022.109455
96. Deng Y, Chi P, Lan P, Wang L, Chen W, Cui L, et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase III trial. J Clin Oncol. 2016;34:3300–7. doi: 10.1200/JCO.2016.66.6198
97. Deng Y, Chi P, Lan P, Wang L, Chen W, Cui L, et al. Neoadjuvant modified FOLFOX6 with or without radiation versus dluorouracil plus radiation for locally advanced rectal cancer: final results of the Chinese FOWARC trial. J Clin Oncol. 2019;37:3223–33. doi: 10.1200/JCO.18.02309
98. Garcia-Aguilar J, Patil S, Gollub MJ, Kim JK, Yuval JB, Thompson HM, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022;40:2546–56. doi: 10.1200/JCO.22.00032
99. Pesantez D, Ten Hoorn S, Machado I, Garcia-Albeniz X, Rodriguez-Salas N, Heredia-Soto V, et al. Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402. J Natl Cancer Inst. 2023;115:1497–505. doi: 10.1093/jnci/djad120
100. Sclafani F, Brown G, Cunningham D, Wotherspoon A, Tait D, Peckitt C, et al. PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer. Ann Oncol. 2016;27:1557–65. doi: 10.1093/annonc/mdw215
101. Garcia-Aguilar J, Chow OS, Smith DD, Marcet JE, Cataldo PA, Varma MG, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015;16:957–66. doi: 10.1016/S1470-2045(15)00004-2
102. Marco MR, Zhou L, Patil S, Marcet JE, Varma MG, Oommen S, et al. Consolidation mFOLFOX6 chemotherapy after chemoradiotherapy improves survival in patients with locally advanced rectal cancer: final results of a multicenter phase II trial. Dis Colon Rectum. 2018;61:1146–55. doi: 10.1097/DCR.0000000000001207
103. Ng SP, Chu J, Chander S, Bressel M, McKendrick J, Wong R, et al. Results of phase II trial of intensified neoadjuvant treatment with interdigitating radiotherapy and chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with locally advanced rectal cancer (PROARCT trial). Radiother Oncol. 2021;155:27–32. doi: 10.1016/j.radonc.2020.10.012
104. Engels B, De Paoli A, Delmastro E, Munoz F, Vagge S, Norkus D, et al. Preoperative radiotherapy with a simultaneous integrated boost compared to chemoradiotherapy for cT3–4 rectal cancer: long-term results of a multicenter randomized study. Cancers (Basel). 2023;15:3869. doi: 10.3390/cancers15153869
105. Yamaguchi T, Akiyoshi T, Fukunaga Y, Sakamoto T, Mukai T, Hiyoshi Y, et al. Adding induction chemotherapy before chemoradiotherapy with total mesorectal excision and selective lateral lymph node dissection for patients with poor-risk, locally advanced, mid-to-low rectal cancer may improve oncologic outcomes: a propensity score-matched analysis. Ann Surg Oncol. 2023;30:4716–24. doi: 10.1245/s10434-023-13458-8
106. Nogue M, Salud A, Vicente P, Arrivi A, Roca JM, Losa F, et al. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study. Oncologist. 2011;16:614–20. doi: 10.1634/theoncologist.2010-0285
107. Benlice C, Koc MA, Gulcu B, Bilgin IA, Akyol C, Baca B, et al. Short-course radiotherapy followed by consolidation chemotherapy is safe and effective in locally advanced rectal cancer: comparative short-term results of multicenter propensity score case-matched study. Dis Colon Rectum. 2023;66:681–90. doi: 10.1097/DCR.0000000000002646
108. Moyer AM, Vogel JD, Lai SH, Kim H, Chin RI, Moskalenko M, et al. Total neoadjuvant therapy in rectal cancer: multi-center comparison of induction chemotherapy and long-course chemoradiation versus short-course radiation and consolidative chemotherapy. J Gastrointest Surg. 2023;27:980–9. doi: 10.1007/s11605-023-05601-3
109. Chin RI, Roy A, Pedersen KS, Huang Y, Hunt SR, Glasgow SC, et al. Clinical complete response in patients with rectal adenocarcinoma treated with short-course radiation therapy and nonoperative management. Int J Radiat Oncol Biol Phys. 2022;112:715–25. doi: 10.1016/j.ijrobp.2021.10.004
110. Hall WA, Li J, You YN, Gollub MJ, Grajo JR, Rosen M, et al. Prospective correlation of magnetic resonance tumor regression grade with pathologic outcomes in total neoadjuvant therapy for rectal adenocarcinoma. J Clin Oncol. 2023;41:4643–51. doi: 10.1200/JCO.22.02525
111. Gollins S, West N, Sebag-Montefiore D, Susnerwala S, Falk S, Brown N, et al. A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS. Br J Cancer. 2018;119:697–706. doi: 10.1038/s41416-018-0209-4
112. Myerson RJ, Tan B, Hunt S, Olsen J, Birnbaum E, Fleshman J, et al. Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer. Int J Radiat Oncol Biol Phys 2014;88:829–36. doi: 10.1016/j.ijrobp.2013.12.028
113. Markovina S, Youssef F, Roy A, Aggarwal S, Khwaja S, DeWees T, et al. Improved metastasis- and disease-free survival with preoperative sequential short-course radiation therapy and FOLFOX chemotherapy for rectal cancer compared with neoadjuvant long-course chemoradiotherapy: results of a matched pair analysis. Int J Radiat Oncol Biol Phys. 2017;99:417–26. doi: 10.1016/j.ijrobp.2017.05.048
114. Kim JK, Marco MR, Roxburgh CSD, Chen CT, Cercek A, Strombom P, et al. Survival after induction chemotherapy and chemoradiation versus chemoradiation and adjuvant chemotherapy for locally advanced rectal cancer. Oncologist. 2022;27:380–8. doi: 10.1093/oncolo/oyac025
115. Garant A, Kavan P, Martin AG, Azoulay L, Vendrely V, Lavoie C, et al. Optimizing treatment sequencing of chemotherapy for patients with rectal cancer: the KIR randomized phase II trial. Radiother Oncol. 2021;155:237–45. doi: 10.1016/j.radonc.2020.11.008
116. Goffredo P, Khan A, Mott SL, Jensen CC, Madoff RD, Gaertner WB, et al. Total neoadjuvant therapy versus standard neoadjuvant chemoradiation in patients with locally advanced rectal cancer: a comparison of short- and long-term oncologic outcomes. Ann Surg. 2022;276:e819–e24. doi: 10.1097/SLA.0000000000005141
117. Cercek A, Roxburgh CSD, Strombom P, Smith JJ, Temple LKF, Nash GM, et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol. 2018;4:e180071. doi: 10.1001/jamaoncol.2018.0071
118. Patel UB, Brown G, Machado I, Santos-Cores J, Pericay C, Ballesteros E, et al. MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial. Ann Oncol. 2017;28:344–53. doi: 10.1093/annonc/mdw616
119. Uehara K, Hiramatsu K, Maeda A, Sakamoto E, Inoue M, Kobayashi S, et al. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial. Jpn J Clin Oncol. 2013;43:964–71. doi: 10.1093/jjco/hyt115
120. Ishii Y, Hasegawa H, Endo T, Okabayashi K, Ochiai H, Moritani K, et al. Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer. Eur J Surg Oncol. 2010;36:1061–5. doi: 10.1016/j.ejso.2010.05.017
121. Mukai T, Uehara K, Aiba T, Ogura A, Tsuzuki T, Tanaka A, et al. Importance of the neoadjuvant rectal (NAR) score to the outcome of neoadjuvant chemotherapy alone for locally advanced rectal cancer. Surg Today. 2020;50:912–9. doi: 10.1007/s00595-020-01964-1
122. Matsuda C, Ishiguro M, Teramukai S, Kajiwara Y, Fujii S, Kinugasa Y, et al. A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial. Eur J Cancer. 2018;96:54–63. doi: 10.1016/j.ejca.2018.03.009
123. Dahl O. Watch your steps, especially when changing treatment for locally advanced rectal cancer. Acta Oncol. 2022;61:1033–5. doi: 10.1080/0284186X.2022.2053574
124. van der Valk MJM, Marijnen CAM, van Etten B, Dijkstra EA, Hilling DE, Kranenbarg EM, et al. Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer – results of the international randomized RAPIDO-trial. Radiother Oncol. 2020;147:75–83. doi: 10.1016/j.radonc.2020.03.011
125. Bauer PS, Gamboa AC, Otegbeye EE, Chapman WC, Rivard S, Regenbogen S, et al. Short-course radiation with consolidation chemotherapy does not increase operative morbidity compared to long-course chemoradiation: a retrospective study of the US rectal cancer consortium. J Surg Oncol. 2023;129:254–63. doi: 10.1002/jso.27468
126. Guida AM, Sensi B, Formica V, D’Angelillo RM, Roselli M, Del Vecchio Blanco G, et al. Total neoadjuvant therapy for the treatment of locally advanced rectal cancer: a systematic minireview. Biol Direct. 2022;17:16. doi: 10.1186/s13062-022-00329-7
127. Sao Juliao GP, Fernandez LM, Vailati BB, Habr-Gama A, Azevedo J, Santiago I, et al. Local regrowth and the risk of distant metastases among patients undergoing watch-and-wait for rectal cancer: what is the best control group? Muticenter retrospective study. Dis Colon Rectum. 2023;73–81. doi: 10.1097/DCR.0000000000002930
128. Hoendervangers S, Couwenberg AM, Intven MPW, van Grevenstein WMU, Verkooijen HM. Comparison of pathological complete response rates after neoadjuvant short-course radiotherapy or chemoradiation followed by delayed surgery in locally advanced rectal cancer. Eur J Surg Oncol. 2018;44:1013–7. doi: 10.1016/j.ejso.2018.03.014
129. Cervantes A, Adam R, Rosello S, Arnold D, Normanno N, Taieb J, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:10–32. doi: 10.1016/j.annonc.2022.10.003
130. Osterlund E, Glimelius B. Temporal development in survival, and gender and regional differences in the Swedish population of patients with synchronous and metachronous metastatic colorectal cancer. Acta Oncol. 2022;61:1278–88. doi: 10.1080/0284186X.2022.2126327
131. Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022;386:2363–76. doi: 10.1056/NEJMoa2201445
132. Wang QX, Xiao BY, Cheng Y, Wu AW, Zhang T, Wang H, et al. Anti-PD-1-based immunotherapy as curative-intent treatment in dMMR/MSI-H rectal cancer: a multicentre cohort study. Eur J Cancer. 2022;174:176–84. doi: 10.1016/j.ejca.2022.07.016
133. Germani MM, Carullo M, Boccaccino A, Conca V, Masi G. The evolving landscape of immunotherapy in locally advanced rectal cancer patients. Cancers (Basel). 2022;14:4453. doi: 10.3390/cancers14184453
134. Osterlund E, Ristimaki A, Makinen MJ, Kytola S, Kononen J, Pfeiffer P, et al. Atypical (non-V600E) BRAF mutations in metastatic colorectal cancer in population and real-world cohorts. Int J Cancer. 2024;154:488–503. doi: 10.1002/ijc.34733
135. Yaeger R, Weiss J, Pelster MS, Spira AI, Barve M, Ou SI, et al. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023;388:44–54. doi: 10.1056/NEJMoa2212419
Published
2024-02-22
How to Cite
Glimelius B. (2024). Recent advances in rectal cancer treatment – are we on the right track?. Upsala Journal of Medical Sciences, 129(S1), e10537. https://doi.org/10.48101/ujms.v129.10537
Issue
Section
Review Articles
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright of their work, with first publication rights granted to Upsala Medical Society. Read the full Copyright- and Licensing Statement.
